Sector News

AstraZeneca R&D boss Morrison leaves to head private drugmaker

June 10, 2015
Life sciences
(Reuters) – AstraZeneca’s chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group’s research operations.
 
A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States, adding there had been no disagreement with other top managers at AstraZeneca.
 
“It is not appropriate for us to confirm the name of the company but it is an exciting new opportunity for him,” she said.
 
Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker’s bid to turn around its portfolio. He also helped defend the firm’s independence in the face of a $118 billion takeover attempt by Pfizer last year.
 
Morrison will cease his current roles at the end of the week and leave AstraZeneca shortly after.
 
While the drugmaker seeks a successor, Chief Executive Pascal Soriot will take over responsibility for medicines development and Elisabeth Bjork will act as chief medical officer.
 
Soriot, who took over as CEO in October 2012, chose Morrison as one of his key drug research lieutenants, alongside Mene Pangalos, who heads early development work, and Bahija Jallal, leader of the group’s MedImmune biotech unit.
 
AstraZeneca has won plaudits for recent progress with its pipeline of experimental drugs, especially in cancer, where it is investing heavily in the hot new field of immunotherapy.
 
Still, many industry analysts remain sceptical about its ability to lift sales to $45 billion by 2023 from $26 billion last year, a target set by Soriot when the company was fighting off Pfizer’s attempted takeover last year.
 
It has suffered some setbacks, too, most recently when its partner Amgen pulled out of a psoriasis drug collaboration last month after suicidal thoughts were observed in patients taking the medicine.
 
AstraZeneca said it had not issued a formal statement about Morrison’s exit because he was not a board member. 
 
By Ben Hirschler (Editing by David Holmes)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”